Published in Fertil Steril on October 01, 2005
Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci (2008) 1.24
2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol (2008) 1.14
Molecular profiling of experimental endometriosis identified gene expression patterns in common with human disease. Fertil Steril (2007) 1.04
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03
Endometriosis as a neurovascular condition: estrous variations in innervation, vascularization, and growth factor content of ectopic endometrial cysts in the rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.00
A baboon model for endometriosis: implications for fertility. Reprod Biol Endocrinol (2006) 0.99
Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am J Pathol (2011) 0.93
Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res (2013) 0.92
A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model. Balkan J Med Genet (2015) 0.82
Peripheral changes in endometriosis-associated pain. Hum Reprod Update (2014) 0.82
Intraperitoneal inflammation decreases endometriosis in a mouse model. Hum Reprod (2008) 0.81
Slit2 overexpression results in increased microvessel density and lesion size in mice with induced endometriosis. Reprod Sci (2012) 0.81
CD13/APN transcription is regulated by the proto-oncogene c-Maf via an atypical response element. Gene (2007) 0.78
Antiangiogenesis therapy of endometriosis using PAMAM as a gene vector in a noninvasive animal model. Biomed Res Int (2014) 0.78
Mouse model of surgically-induced endometriosis by auto-transplantation of uterine tissue. J Vis Exp (2012) 0.78
Antiangiogenic therapies in endometriosis. Br J Pharmacol (2006) 0.78
Endometriosis: alternative methods of medical treatment. Int J Womens Health (2015) 0.76
Pigment epithelium derived factor inhibits the growth of human endometrial implants in nude mice and of ovarian endometriotic stromal cells in vitro. PLoS One (2012) 0.76
Chronic effects of an anti-angiogenic thrombospondin-1 mimetic peptide, ABT-898, on female mouse reproductive outcomes. Reprod Biol Endocrinol (2016) 0.75
Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 3.10
SOS: can we save pediatric radiology? Radiology (2005) 2.98
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol (2012) 2.61
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature (2004) 2.48
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
Effect of an imaging protocol on clinical outcomes among pediatric patients with appendicitis. Pediatrics (2002) 2.47
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ Res (2007) 2.12
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
A clinical decision rule to identify children at low risk for appendicitis. Pediatrics (2005) 2.06
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol (2008) 1.93
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr (2009) 1.89
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
The mouse cornea micropocket angiogenesis assay. Nat Protoc (2007) 1.74
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics (2005) 1.72
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70
Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther (2002) 1.67
Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr (2009) 1.66
Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res (2005) 1.64
Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics (2006) 1.60
Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg (2005) 1.59
Radiation exposure reduction during voiding cystourethrography in a pediatric porcine model of vesicoureteral reflux. Radiology (2006) 1.59
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57
Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat (2010) 1.57
Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J (2006) 1.52
Forty-year journey of angiogenesis translational research. Sci Transl Med (2011) 1.51
Patient size measured on CT images as a function of age at a tertiary care children's hospital. AJR Am J Roentgenol (2010) 1.47
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract (2014) 1.47
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem (2007) 1.46
Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J (2008) 1.46
Sonographic imaging of the posterior fossa utilizing the foramen magnum. Pediatr Radiol (2010) 1.45
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res (2004) 1.42
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med (2006) 1.42
Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility. Cancer (2014) 1.41
Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis (2008) 1.38
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res (2005) 1.33
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res (2005) 1.33
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33
Has pediatric CT at children's hospitals reached its peak? AJR Am J Roentgenol (2010) 1.31
Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A (2005) 1.28
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res (2002) 1.28
Platelet-associated PF-4 as a biomarker of early tumor growth. Blood (2007) 1.26
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
Lymphangiogenesis new mechanisms. Ann N Y Acad Sci (2002) 1.23
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23
Radiation abscopal antitumor effect is mediated through p53. Cancer Res (2003) 1.22
Pediatric radiation exposure and effective dose reduction during voiding cystourethrography. Radiology (2008) 1.21
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol (2008) 1.19
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res (2004) 1.19
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol (2008) 1.18
Tumor-vascular interactions and tumor dormancy. APMIS (2008) 1.16
Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol (2003) 1.16
2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol (2008) 1.14
DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism. J Biol Chem (2001) 1.13
The effect of genetic diversity on angiogenesis. Exp Cell Res (2006) 1.13
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.12
VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis (2012) 1.12
Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics (2002) 1.12
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol (2008) 1.11
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
Pediatric abdominal pain: use of imaging in the emergency department in the United States from 1999 to 2007. Radiology (2012) 1.11
A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res (2005) 1.10